Steve Brown and Lisa Booth sat down for a joint interview with CURE to discuss the future of patient-driven artificial intelligence in cancer care.

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

CureWise, the AI-powered platform Steve originally developed to help with his own rare blood cancer diagnosis, has evolved ...

Steve Brown and Lisa Booth sat down for a joint interview with CURE to discuss the future of patient-driven artificial intelligence in cancer care.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...

Jeannine Walston has a survivorship story of more than 25 years to share. Walston, who has contributed to CURE as a blogger ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...

CURE had the privilege of attending the Hairy Cell Leukemia Foundation 2025 Conference in Bologna, Italy, where medical experts gathered to discuss advances in research, treatment ...

While October promotes awareness through campaigns, ribbons and fundraising, survivors report a more complex reality. Breast cancer survivor Maureen Green described the month as a reminder of the ...

PhD in clinical psychology. She is a senior psychologist, director of Interprofessional Education and director of the Young Adult Program (YAP) in the Department of Supportive Oncology at Dana-Farber ...

“Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers,” by Dewpoint Therapeutics. News release; Oct. 21, 2025. For more news on cancer ...